Since MTAP deletion happens frequently in osteosarcoma and its synthetic lethality pair PRMT5 inhibitor might target normal cells in vivo, our microrobots might become a new delivery approach to deliver the synthetic lethal drug directly to the tumor site to enhance the drug efficiency and reduce the side effects. This evidence concerns the gene PRMT5 and neoplasm.